Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cyproterone Acetate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 7/20 | 1.00 |
| ▸ | PGR known ✓ | P06401 | 7/20 | 1.00 |
| ▸ | AR known ✓ | P10275 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 0.72 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.72 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.66 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.66 |
| ▸ | USP2 | O75604 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyproterone Acetate SCHEMBL6061433 | 1.00 | NR3C1 (1.00) | NR3C1CYP3A4PGRARLMNA | |
| Cyproterone Acetate SCHEMBL21540064 | 1.00 | NR3C1 (1.00) | NR3C1CYP3A4PGRARLMNA | |
| Cyproterone Acetate SCHEMBL11801394 | 1.00 | NR3C1 (1.00) | NR3C1CYP3A4PGRARLMNA | |
| Cyproterone Acetate SCHEMBL8021230 | 1.00 | NR3C1 (1.00) | NR3C1CYP3A4PGRARLMNA | |
| Cyproterone Acetate SCHEMBL11795995 | 1.00 | NR3C1 (1.00) | NR3C1CYP3A4PGRARLMNA | |
| Cyproterone Acetate SCHEMBL15780914 | 1.00 | NR3C1 (1.00) | NR3C1CYP3A4PGRARLMNA | |
| Cyproterone Acetate SCHEMBL20459065 | 1.00 | NR3C1 (1.00) | NR3C1CYP3A4PGRARLMNA | |
| Cyproterone Acetate SCHEMBL9800274 | 1.00 | NR3C1 (1.00) | NR3C1CYP3A4PGRARLMNA | |
| Cyproterone Acetate SCHEMBL7857093 | 0.98 | NR3C1 (0.96) | NR3C1CYP3A4PGRARLMNA | |
| Cyproterone Acetate SCHEMBL7867230 | 0.97 | NR3C1 (0.94) | NR3C1CYP3A4PGRARLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 26593 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125761-A1 | PREDICTION OF AN OUTCOME OF NEOADJUVANT ANDROGEN DEPRIVATION THERAPY IN A PROSTATE CANCER SUBJECT | KONINKLIJKE PHILIPS NV (NL) | 2026-05-07 | — | — | US | claimed |
| EP-4735045-A2 | OXAZAPHOSPHORINE ANTIBODY DRUG CONJUGATES AND METHODS OF USE | La Life Products, LLC (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4440706-B1 | COMPOSITIONS FOR PROMOTING HAIR GROWTH | ESTETRA SRL (BE) | 2026-04-29 | — | — | EP | claimed |
| US-20260078142-A1 | FULLY-CONTINUOUS SYNTHESIS METHOD OF CYPROTERONE ACETATE | UNIV FUDAN (CN) | 2026-03-19 | — | — | US | claimed |
| EP-4525938-B1 | RADIOPHARMACEUTICAL COMPLEXES TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND ITS COMBINATIONS | BAYER AG (DE) | 2026-03-11 | — | — | EP | claimed |
| US-20260060913-A1 | BIOACTIVE WALNUT PEPTIDES FOR TREATING HAIR LOSS | L'OREAL (FR) | 2026-03-05 | — | — | US | claimed |
| US-20260053736-A1 | LONG ACTING DRUG DELIVERY DEVICE AND ITS USE IN CONTRACEPTION | BAYER OY (FI) | 2026-02-26 | — | — | US | claimed |
| EP-4691556-A2 | HUMANIZED ANTI-ACTH ANTIBODIES AND USE THEREOF | H. Lundbeck A/S (DK) | 2026-02-11 | — | — | EP | claimed |
| US-12533359-B2 | Method for preventing hair loss | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2026-01-27 | — | — | US | claimed |
| EP-4463570-B1 | METHOD FOR HORMONE OR DRUG SCREENING IN A TISSUE SAMPLE | ECOLE POLYTECHNIQUE FED LAUSANNE EPFL (CH) | 2026-01-14 | — | — | EP | claimed |
| US-4396615-A | STEROIDS, SKIN DISORDERS | DUKE UNIVERSITY (US) | 1983-08-02 | — | — | US | claimed |
| US-4367227-A | Method and cosmetic composition for reducing sebum secretion | LEVER BROTHERS COMPANY (US) | 1983-01-04 | — | — | US | claimed |
| US-4344942-A | ESTROGEN INHIBITION | FINCHIMICA S.R.L. (IT) | 1982-08-17 | — | — | US | claimed |
| US-4310510-A | Self administrable anti-fertility composition | SHERMAN KENNETH N | 1982-01-12 | — | — | US | claimed |
| US-4310523-A | Combined antiestrogens and antigonadotropically effective antiandrogens for the prophylaxis and therapy of hyperplasia of the prostate | SCHERING AKTIENGESELLSCHAFT (DE) | 1982-01-12 | — | — | US | claimed |
| US-4252787-A | CONTRACEPTIVES, PROGESTATIONAL ACTIVITY, STEROIDS | CAMBRIDGE RESEARCH AND DEVELOPMENT GROUP (US) | 1981-02-24 | — | — | US | claimed |
| US-4145416-A | ESTRADIOL AND ESTRIOL DERIVATIVES | SCHERING, A.G. (DE) | 1979-03-20 | — | — | US | claimed |
| US-4034749-A | Intrauterine contraceptive device | SCHERING AKTIENGESELLSCHAFT (DT) | 1977-07-12 | — | — | US | claimed |
| US-3969502-A | 17-ALPHA ETHYNYLESTRADIOL AND NORGESTREL OR 17-ETHYNYL-19-NORTESTERONE ACETATE | SCHERING AKTIENGESELLSCHAFT (DT) | 1976-07-13 | — | — | US | claimed |
| US-3957982-A | AN ESTROGEN AND A PROGESTOGEN | SCHERING AKTIENGESELLSCHAFT (DT) | 1976-05-18 | — | — | US | claimed |